A Phase 1/2 interventional study of Artemisias-ginger patch (AGP) and Sham (No Treatment) in End Stage Chronic Renal Failure and Myofacial Pain, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Chang Gung Memorial Hospital · Phase 1/2, Interventional, and Treatment
To evaluate the effect of a traditional Chinese medicine (TCM) intervention on pain relief, mood and quality of life (QOL) in hemodialytic patients at a dialysis center in Southern Taiwan.
3,144 studies on the registry are indexed under Renal Insufficiency, Chronic; 704 are open to participants now.
This study's enrollment of 21 is below the median of 74 across 2,176 interventional studies indexed under Renal Insufficiency, Chronic.
Browse Renal Insufficiency, Chronic studies →Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Sham (No Treatment)
Other: Artemisias-ginger patch (AGP)
The TCM powder using extract powder that consists of Draconis Sanguis, Rz. Zingiberis Recens, and Artemisia princeps had been formulated into uniform 3X3 cm patch under the supervision of senior pharmacists. The 3 acupoints applied by study drug were LI 10, LU 5 and TE 5 with HD three times a week for 4 weeks.
The sham HAT was applied on 3 acupoints including LI 10, LU 5 and TE 5 with HD three times a week for 4 weeks.
Brief Pain Inventory (BPI)
Pain severity and interference are rated on a numerical rating scale (NRS) from 0 ("no pain"/"does not interfere") to 10 ("worst imaginable pain"/"completely interferes").
Time frame: Weeks 0 (baseline), 2, 4, and 6 (2 weeks of follow-up)
Health Questionnaire Depression Rating Scale (PHQ-9)
PHQ-9 is a 9-item, self-administered diagnostic tool used to screen for, diagnose, monitor, and measure the severity of depression in primary care and mental health settings. It scores symptoms based on the DSM-5 criteria over the past two weeks, with a total score ranging from 0 to 27.
Time frame: Week 0 (baseline) and 4
EuroQol-5-dimension questionnaire (EQ-5D)
The EQ-5D consists of five dimensions that are rated on a 3-point scale, where lower scores indicate better health status
Time frame: Week 0(baseline) and 4
Routine blood analysis
The outine blood analysis includes CBC, Kt/V, K, Ca, P, K, albumin, hsCRP, AST, and ALT.
Time frame: Week 0(baseline) and 4
Total number of analegics use in all HD sessions
Frequency of pain management including local analgesics, cryotherapy and oral painkillers during each dialysis was assessed within 12 sessions of study and was calculated by the number of participants in total.
Time frame: Week 4
Total number of early termination of hemodialysis
Total number of stopping the dialysis machine before the scheduled time (e.g., less than 4 hours) during 4-week treatment
Time frame: Week 4
Plan to share: Undecided — Data is being compiled and is expected to be submitted.
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital